

Agenda:

Agenda
Introduction to the Challenge
Individual Workstream Overview
Evaluation Expectations
Procurement Overview
Q&A
Next Steps and Meeting Close

Overview:

The 'Data to Early Diagnostics and Precision Medicine' Challenge has been developed through the ISCF process and Government's Life Sciences Industry Strategy, and a Sciences Sector Deal 1, with an announced support of £210 million over five years from 2017/18 to 2022/23. The Challenge embraces three delivery streams:

- Genomics - to ensure that the UK leads in exploiting large scale whole genome sequencing for precision medicine. An investment through UKRI of £100m in whole genome sequencing and linked informatics has levered another £150m from a consortium of industry (four pharma) and Wellcome Trust, allowing whole genome sequencing and informatics on all 500,000 UK Biobank participants. In parallel, tumour/germline pairs sequencing will be explored in partnership with Genomics England (GeL).
- Centres for digital pathology, radiology, AI and machine learning and enabling integrated **diagnostics** – to create a network of Centres of Excellence in digital pathology and in-vivo imaging and to maximise the utility of the images and processes with AI and digital systems for the benefit of industry, researchers, clinicians and the NHS. The integrated diagnostics CR&D investment will challenge companies to work with the UK healthcare and research infrastructure to deliver solutions for early diagnosis and precision medicine. Total ISCF investment £66m
- Digital Innovation Hub Programme (DIHP) – To offer businesses local access to federated UK-wide data, the DIHP will link routine NHS data with rich data from R&D programmes and provide analytic tools and informatics support for businesses. A £37.5m ISCF funding is earmarked to overlay

broader, digital-ready data platforms for industry, aligning with NHS England investments for regional investments in Integrated Health and Care Records

The evaluation is split into four distinct stages:

There will be a break clause in the contract at the end of each phase where UKRI will make a decision on the contract continuing. Bidders are required to cost each phase separately. The four phase headlines are as follows:

Phase 1 -Evaluation Framework Development

Phase 2 – Baseline measurement

Phase 3 – Process evaluation and interim progress reporting on evaluation

Phase 4 – Impact evaluation

In addition to this regular progress update are required to the ISCF Challenge Evaluation Manager throughout the project.

More detail will be provided at the pre-engagement event and is also included in the tender documents which will be released once the tender is live.